Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

Günter Niegisch; Anja Lorch; Michael J Droller; Hugh J Lavery; Kristian D Stensland; Peter Albers

doi:10.1016/j.eururo.2013.06.002

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

Eur Urol. 2013 Sep;64(3):355-7. doi: 10.1016/j.eururo.2013.06.002. Epub 2013 Jun 12.

Authors

Günter Niegisch¹, Anja Lorch, Michael J Droller, Hugh J Lavery, Kristian D Stensland, Peter Albers

Affiliation

¹ Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany.

PMID: 23773558
DOI: 10.1016/j.eururo.2013.06.002

Abstract

Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.

MeSH terms

Chemotherapy, Adjuvant
Cystectomy* / adverse effects
Cystectomy* / mortality
Cystectomy* / standards
Evidence-Based Medicine
Humans
Neoadjuvant Therapy* / adverse effects
Neoadjuvant Therapy* / mortality
Neoadjuvant Therapy* / standards
Neoplasm Invasiveness
Neoplasm Staging
Patient Selection*
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Urinary Bladder Neoplasms / mortality
Urinary Bladder Neoplasms / pathology
Urinary Bladder Neoplasms / therapy*